Access Statistics for Johann Matthias Graf von der Schulenburg

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Cost of Poor Adherence to Anti-Hypertensive Therapy in Europe 0 0 0 23 0 0 2 122
Cost of poor adherence to anti-hypertensive therapy in five European countries 0 0 0 0 0 0 19 39
Grundlagen und Methoden von GKV-Routinedatenstudien 0 0 0 21 2 2 22 104
Total Working Papers 0 0 0 44 2 2 43 265


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Affirmative and silent cyber coverage in traditional insurance policies: Qualitative content analysis of selected insurance products from the German insurance market 0 0 1 13 1 1 3 127
Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments 0 0 2 5 1 2 5 12
An Urban Crisis Management System for Critical Infrastructures: Participation Possibilities for Insurance Companies 0 1 1 13 0 1 1 84
Analysis of Driving Factors of Willingness to Use and Willingness to Pay for Existing Pharmacological Smoking Cessation Aids Among Young and Middle-Aged Adults in Germany 0 0 0 1 0 0 0 29
Benefit assessment in Germany: implications for price discounts 0 0 0 5 2 3 4 39
Bonus options in health insurance by Peter Zweifel. Awer Academic Publishers, Dordrecht, 1992. No. of ges: xii + 141. ISBN 0‐7923‐1722‐X 0 0 0 2 0 0 0 8
COVID-19: not the time for health economists? A plea for more proactive health economic involvement 0 0 0 3 0 0 0 16
Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer 0 0 0 25 0 0 0 104
Commentary 0 0 0 0 1 1 2 17
Corporate Management of Highly Dynamic Risks: Evidence from the Demand for Terrorism Insurance in Germany 0 0 0 18 0 3 4 56
Correction to: An Urban Crisis Management System for Critical Infrastructures: Participation Possibilities for Insurance Companies 0 0 0 1 0 0 0 13
Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany 0 0 0 2 1 1 1 52
Costs and treatment patterns of incident ADHD patients - a comparative analysis before and after the initial diagnosis - 0 0 0 1 0 0 2 22
Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study 0 0 0 5 0 1 1 74
Diffusion of innovations: treatment of Alzheimer's disease in Germany 0 0 1 39 0 0 1 191
Digital Transformation in Back-Offices of German Insurance Companies 0 2 14 16 2 7 37 42
EJHE has an official impact factor of 1.337 0 0 0 10 0 1 3 117
Editor’s note 0 0 0 2 0 0 0 16
Entwicklung der Leistungsempfängerzahlen in der Gesetzlichen Pflegeversicherung - Zum Einfluss unterschiedlicher Morbiditätsannahmen auf die Entwicklung der sozialrechtlich anerkannten Pflegebedürftigkeit in Deutschland 0 0 0 10 0 1 1 36
German Value Set for the EQ-5D-5L 0 0 1 5 1 2 6 47
German health care system in transition 0 0 0 13 0 0 1 51
Greetings from the Editors 0 0 0 2 0 1 1 25
HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies 0 0 0 16 0 1 3 98
Impact of radiofrequency ablation for patients with varicose veins on the budget of the German statutory health insurance system 0 0 1 6 0 0 1 45
Impact of the Introduction of the Social Long-Term Care Insurance in Germany on Financial Security Assessment in Case of Long-Term Care Need&ast 0 0 0 23 0 0 1 143
Letter from the editors 0 0 0 3 0 0 0 16
Measuring economic consequences of preterm birth - Methodological recommendations for the evaluation of personal burden on children and their caregivers 0 0 0 6 0 0 0 52
Measuring patients’ priorities using the Analytic Hierarchy Process in comparison with Best-Worst-Scaling and rating cards: methodological aspects and ranking tasks 0 0 0 2 1 1 2 19
Nach welchen ökonomischen Methoden sollten Gesundheitsleistungen in Deutschland evaluiert werden? / According to Which Economic Methods Should Health Care Services Become Evaluated in Germany? 0 0 0 13 0 1 1 102
On the Impact of the Financial Crisis on the Dividend Policy of the European Insurance Industry 0 0 0 227 2 2 2 821
Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany 0 0 0 6 1 1 2 70
Promoting vaccinations - an analysis of measures taken by German statutory health insurers 0 0 0 8 0 1 1 41
Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems 0 0 0 6 0 1 2 29
Regional differences in health care of patients with inflammatory bowel disease in Germany 0 0 0 5 1 1 1 44
Reinsurance Brokers and Advice Quality: Is There a Need for Regulation&quest 0 0 1 21 0 0 3 154
Reliability of Risk Management: Market Insurance, Self-Insurance and Self-Protection Reconsidered 0 0 0 46 0 0 0 162
Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe 0 0 0 4 0 0 0 35
Validating the EQ-5D with time trade off for the German population 0 0 0 30 1 1 1 119
Voting on Social Security: The Family as Decision‐Making Unit 0 0 0 3 0 0 0 4
“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations 0 0 0 5 2 3 3 42
Total Journal Articles 0 3 22 621 17 38 96 3,174


Statistics updated 2025-03-03